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ABSTRACT 
Background: Patients with a systemic right ventricle (RV) have a compromised late outcome 
caused by ventricular dysfunction. Standard medical heart failure therapy has not been shown to 
improve RV function and survival in these patients. Phosphodiesterase (PDE)-5 inhibition 
increases contractility in experimental models of RV hypertrophy, but not in the normal RV. In 
clinical practice, the effects of PDE-5 inhibition on systemic RV function and exercise capacity in 
adults with a systemic RV have not been tested.  
 
Methods: The SERVE protocol is a double-blind, randomized placebo-controlled multicenter 
superiority trial to study the effect of PDE-5 inhibition with Tadalafil on RV volumes and function 
in patients with either D-transposition of the great arteries repaired with an atrial switch 
procedure or with congenitally corrected transposition of the great arteries. Tadalafil 20 mg or 
placebo will be given over a study period of 3 years. The primary endpoint is the change in mean 
end-systolic RV volumes from baseline to study end at 3 years of follow-up (or at the time of 
permanent discontinuation of the randomized treatment if stopped before 3- years of follow-up), 
and will be measured by cardiovascular magnetic resonance imaging (CMR) or by cardiac 
computed tomography in patients with contraindications for CMR. Secondary endpoints are 
changes in RV ejection fraction, VO2max and NT-proBNP. 
 
Conclusion: The objective of this study is to assess the effect of PDE-5 inhibition with Tadalafil 
on RV size and function, exercise capacity and neurohumoral activation in adults with a systemic 
RV over a 3-year follow-up period.  
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1. Introduction 
The number of adults with congenital heart disease (CHD) continues to increase.[1] Residual 
lesions and sequelae of previous interventions predispose to higher morbidity and increased 
mortality rates.[2] Adult patients with prior atrial switch operations (i.e. Senning or Mustard 
procedures) for complete transposition of the great arteries (d-TGA) or adults with congenitally 
corrected transposition of the great arteries (ccTGA) and no switch procedure have the right 
ventricle (RV) in subaortic (systemic) position.[3] Although midterm survival is favorable, late 
outcome is compromised by ventricular dysfunction of the systemic RV often leading to end-
stage heart failure and premature death.[4-8]  
Medical heart failure therapy with angiotensin-converting-enzyme inhibitors (ACE-I), angiotensin 
II receptor blockers (ARBs), beta-blockers, and aldosterone antagonists has been shown to 
improve ventricular function and survival in patients with left ventricular (LV) failure from 
acquired heart disease.[9] However, several studies failed to show a similar clinical benefit of 
these drugs in adults with a failing systemic RV.[10-21] Currently, the only established therapy 
for end-stage heart failure in patients with a systemic RV is heart transplantation.[22] Ventricular 
assist devices can be used as bridge to transplant.[23, 24] Given the ubiquitous shortage of 
donor organs and the number of adults at risk, medical options to improve the fate of a systemic 
RV are urgently needed.  
To the best of our knowledge, the effects of PDE-5 inhibition on RV function and exercise 
capacity have not yet been tested in adults with a systemic RV. The aim of the present study is 
to assess in a double-blind, randomized, placebo-controlled trial the effect of PDE-5 inhibition 
with Tadalafil on RV size and function, exercise capacity and neurohumoral activation in adults 
with a systemic RV over a 3-year follow-up.  
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2. Study design and setting of the study 
This study will use a parallel group, double-blind, randomized, placebo-controlled, multi-center, 
superiority trial design. Patients meeting the inclusion and exclusion criteria will be allocated 
randomly to Tadalafil vs. placebo treatment in a 1:1 ratio at the screening visit, using a web-
based randomization system. Randomization will be stratified by pacemaker implant at 
screening. The study is registered at ClinicalTrials.gov (Identifier: NCT03049540). 
The primary objective is to assess the effects of Tadalafil on systemic RV endsystolic volume 
(ESV) measured by cardiovascular magnetic resonance imaging (CMR) or cardiac multirow 
detector computed tomography (CMDCT) - in patients with contraindications for cardiac MRI – 
after 3 years of therapy. As our aim is to study the effect of Tadalafil in an unselected group of 
patients with systemic right ventricles, only few criteria for exclusion were defined and all eligible 
patients are asked for participation. Our main goal is to define the effect of Tadalafil on long-term 
outcome and thus a study-duration of three years was chosen. However, to secure the primary 
endpoint we opted to add an additional MRI-study at one year of follow-up. 
 The secondary objective of this study is to assess the effects of Tadalafil on systemic RV 
ejection fraction (EF) measured by CMR or CMDCT at 3 years of follow-up. Another secondary 
objective of this study is to assess the effects of PDE-5 inhibition on exercise capacity and on 
serum neurohormonal activation in these patients at 3 years of follow-up. The long-term safety of 
Tadalafil and its tolerability will be studied in terms of incidence of the following adverse events 
(AE):  headache (reported > 10%), epipharyngitis (reported > 10%), nausea and dyspepsia 
(reported > 10%) and symptomatic arterial hypotension (reported 1-10%) and in terms of serious 
adverse event (SAE) such as hospitalization for heart failure or death. 
The inclusion and exclusion criteria are detailed in Table 1. All participants will be started on 
Tadalafil 20 mg or placebo OD without any titration period. 
Follow-up 
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After the baseline inclusion visit and a first follow-up visit after four weeks, further follow-up will 
consist of yearly outpatients visits and phone calls after 3, 6, 9, 18 and 30 months to control the 
adherence to the study drug, and to assess the concomitant medication and record and 
document AE and SAE. The rational to follow participants at yearly intervals after the first year of 
the study follows requirements of standards of care, defined by the Swiss Working Group for 
Adults with Congenital heart disease.[25]  
 
 
Table 2 summarizes the assessment schedule.  
 
3. Methods 
3.1 CMR and CMDCT 
CMR will be performed in all patients at baseline, at 1 year and at 3-year follow-up. Image 
acquisition will be performed with a 1.5-T scanner using a standardized protocol to diminish 
inter-study variability between the different centers. A position paper of a the group of Swiss 
pediatric and adult cardiologists and radiologists performing CMR in congenital heart disease at 
university hospitals in Switzerland has been published. The recommendations for imaging a 
systemic RV as outlined in this paper will be followed for this trial.[26] 
In patients with contraindication for CMR, CMDCT will be performed at baseline, at 1 year and at 
3-year follow-up to establish the primary endpoint. Images will be obtained by contrast-
enhanced, electrocardiogram (ECG) gated cardiac MDCT in cranio-caudal direction during 
inspiratory breath hold. Axial images of 10 cardiac phases are acquired in steps of 10% of the R-
R interval. To depict the whole heart, 60-80 slices are made each with 2 mm thickness and no 
interslice gap. From these, 12-15 short-axis reconstructions will be created for functional 
analysis.  
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In both imaging methods, cine loops will be used to define end diastole (largest RV volume) and 
end systole (smallest RV volume). Trabeculations and papillary muscles will be considered part 
of the ventricular cavity. The sum of traced contours in end diastole and end systole will be used 
to calculate end-diastolic and end-systolic volumes using a disc summation method.[26]  
To minimize bias in image analysis, measurements of ventricular volumes and function will be 
performed in a blinded fashion by experienced observers in a core lab for CMR data 
(“swissCVIcorelab” at the Centre Hospitalier Universitaire Vaudois, CHUV, Switzerland) and for 
CMDCT data (University Hospital Zurich, Switzerland).. To decrease the variability in RV ESV, 
every measurement will be performed twice, by 2 different readers, and the mean volume will be 
used for study purposes. 
3.2 Cardiopulmonary exercise testing (CPET) 
Cardiopulmonary exercise testing (CPET) will be performed in all patients at baseline and at 
study end. Before exercise, respiratory flow loops will be acquired and maximal breathing 
capacity determined. Patients will be placed on a cycle ergometer to perform continuous 
measurements of minute ventilation, oxygen consumption, carbon dioxide production, heart rate, 
blood pressure and electrocardiography. Workload will be increased by 5 to 15 Watts in a 
stepwise manner, depending on the individually predicted maximum exercise capacity, in such a 
way that maximal possible effort can be attained in 10-15 minutes. Peak VO2 is defined as the 
highest value of oxygen consumption during the last 30 s of peak exercise. A 12-lead ECG will 
be continuously recorded and a finger pulse oxymeter is used for continuous measurement of 
arterial oxygen saturation. The following additional parameters will be assessed: VE/VCO2 
Slope, PETCO2, O2 pulse trajectory, delta VO2/delta W trajectory, heart rate kinetics and heart 
rate recovery (HRR). Measurements and reporting of these data will follow the recommendations 
of the European Association for Cardiovascular Prevention and Rehabilitation.[27] The analysis 
of CPET data will be performed at a single core-lab, located at the University Hospital Inselspital. 
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3.3 Neurohumoral activation 
Neurohumoral activation will be measured in all patients at baseline, at 1 year and at study end. 
Concentrations of the neurohormones B-type natriuretic peptides (BNP), N-terminal pro-brain 
natriuretic peptide (NT-proBNP), high-sensitive cardiac troponin (hs-cTn), A-type natriuretic 
peptide (MR-proANP), Pro-adrenomedullin, Copeptin and Pro-endothelin-1 will be measured at 
a single core-lab with expertise in biomarkers (Cardiovascular Research Institute Basel, CRIB).  
Specific patients sets with plastic tubes and barcodes corresponding to the individual patient 
numbers and time points in the study will be used. Samples will be collected locally, followed by 
centrifugation, aliquoting and initial storage at -80 degrees at every center. Regular pick up of 
samples at the individual hospitals and transport to the dedicated biobank at the CRIB will be 
provided by the core-lab.  
4. Statistical considerations and sample size 
4.1 Hypothesis 
All primary and secondary endpoints will be analysed by intention-to-treat, tested using two-
sided superiority testing with alpha set at 5%. The primary hypothesis tested is that patients 
randomized to treatment with Tadalafil will improve systemic RV ESV compared to the patients 
randomized to treatment with placebo. In patients who have to discontinue the study medication 
prematurely, RV ESV will be re-measured within 4 weeks of the study drug withdrawal and this 
measurement will then be used for the primary endpoint analyses, unless the treatment period 
was < 3 months. The difference in RV ESV between baseline and the last CMR / CMDCT 
measurement will serve as primary endpoint.  
Secondary endpoints are change in RV EF measured by CMR or CMDCT, change in exercise 
capacity measured as peak VO2 during cardiopulmonary exercise testing and change in serum 
neurohormonal activation (seven biomarkers: BNP, NT-pro BNP, hs-cTn, MR-proANP, Pro-
adrenomedullin, Copeptin and Pro-endothelin-1) from baseline to study end at 3 years of follow-
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up or at the time of permanent discontinuation of the randomized treatment if stopped before 3 
years of follow-up. Again, in patients who have to discontinue the study medication prematurely, 
RV EF, exercise capacity and neurohumoral activation will be re-measured within 4 weeks of the 
study drug withdrawal, unless the treatment period was < 3 months. 
4.2 Sample size 
The sample size calculation is based on the primary endpoint - the change in RV ESV. In a 
representative sample of n=79 TGA patients with a systemic RV from Bern and Zurich with CMR 
data, the RV end-systolic volume was 122±34 ml.[28] Assuming that RV ESV improve or remain 
stable in the Tadalafil group and increase by 20% in the Placebo group to 146±39 ml, 78 
patients are required to obtain an 80% power to detect this difference in RV end-systolic 
volumes between the 2 treatment groups. Considering a possible dropout of 20%, 98 patients 
will be required (49 patients for each group). Assuming that not all RV may respond similarly to 
Tadalafil, we elected to account for this phenomenon by increasing the standard deviation in the 
follow-up exam from 34 ml to 39 ml.  
 
4.3 Primary analysis  
The primary endpoint will be analysed using ANCOVA (Analysis of Covariance), with RV ESV (in 
ml) at 3 years (or earlier if drug withdrawal) as the response variable, randomized treatment as 
main independent variable, baseline RV ESV (ml) and time between baseline and follow-up RV 
volume measurement (in months since baseline) as covariates.  
 
4.4 Secondary analyses  
Secondary endpoints will be analysed using ANCOVA (Analysis of Covariance) or Tobit 
regression or Multiple Imputation ANCOVA, with the secondary endpoint (RV EF, peak VO2, 
BNP, NT-pro BNP, hs-cTn, MR-proANP, Pro-adrenomedullin, Copeptin or Pro-endothelin-1) at 3 
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years (or earlier if drug withdrawal) as the response variable, randomized treatment as main 
variable, baseline measurement (RV EF, peak VO2, BNP, NT-pro BNP, hs-cTn, MR-proANP, 
Pro-adrenomedullin, Copeptin or Pro-endothelin-1; respectively) and time between baseline and 
follow-up measurement time (in months since baseline) as covariates.  
 
5. Ethical considerations 
The study will be carried out according to the ICH GCP Guidelines. It will be submitted to the 
responsible ethics committee and to the competent authorities. The clinical study can only begin 
once approval from all required authorities has been received. Any additional requirements 
imposed by the authorities will be implemented. Serious Adverse Events and adherence to the 
study drug will be carefully monitored and reviewed during the study by an independent Data 
Safety Monitoring Board.  
This is a first clinical trial within this patient population with this study drug and the success of the 
treatment cannot be predicted. The safety profile of the drug and the lack of treatment for these 
specific patients justify the conduct of the study from an ethical point of view. 
 
6. Discussion 
We present a double-blind, randomized placebo controlled multicenter superiority trial to study 
the effect of PDE-5 inhibition with Tadalafil on RV volumes and function in patients with either D-
transposition of the great arteries repaired with an atrial switch procedure or with congenitally 
corrected transposition of the great arteries. The rationale to conduct this study is the fact that 
currently available medical heart failure therapy, proven to work for heart failure in acquired 
heart disease, failed in trials that sought preventing RV dysfunction and heart failure with these 
agents in patients with a systemic RV.  
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Explanation for choice of the drug an its dose 
Considering the negative trials with conventional left heart failure medication, one can argue that 
in the setting of a failing systemic RV the pursuance of therapies developed for treatment of LV 
failure has to be abandoned and novel approaches have to be investigated.[10] 
The RV and LV have different embryological origins, myocardial architecture and contractile 
properties.[29, 30] In response to increased afterload, as present in an RV in systemic position, 
the RV expresses a fetal gene pattern with an increase in phosphodiesterase-5 (PDE-5) 
expression.[31] PDE-5 is not expressed in the normal RV, but is up-regulated in hypertrophied 
RV myocardium. PDE-5 inhibitors increase contractility in experimental models of RV 
hypertrophy, but not in the normal RV.[31] In a rat model of fix RV pressure load after pulmonary 
artery banding, PDE-5 inhibition with Sildenafil had a positive effect on RV diastolic function and 
attenuated interstitial fibrosis in animals with established RV dysfunction, independent from 
afterload.[32] 
In pulmonary arterial hypertension (PAH) patients, Sildenafil and Tadalafil are the most widely 
used PDE-5 inhibitors. Tadalafil has a longer half-live (18 hours) than Sildenafil (3-4 hours) and 
higher selectivity for PDE-5.[33] Tadalafil can be taken as a single daily dose. In studies 
investigating the effects of Tadalafil on cardiac and circulatory function, single Tadalafil doses up 
to 50 mg have been reported to be safe in terms of an absence of significant systemic 
vasodilation.[33] In several large PAH trials, Tadalafil therapy was well tolerated through up to 
68 weeks of dosing.[34, 35] In the large number of patients using PDE-5 inhibitors for treating 
erectile dysfunction, Tadalafil had an excellent safety profile without significant cardiovascular 
safety issues.[36] In over 30 trials, more than 12’000 men (mean age 55 years) with erectile 
dysfunction received Tadalafil and 2’000 men (mean age 56 years) received placebo. Tadalafil 2 
mg to 50 mg was taken as needed, 3 times/week, or once a day. Across all trials, the incidence 
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rate of serious cardiovascular events was similar in Tadalafil-treated men compared to placebo-
treated ones.[37]  
For all these reasons, we decided to use Tadalafil as PDE-5 inhibitor in this clinical study. In the 
PHIRST trial, a study with PAH patients, Tadalafil 2.5 mg, 10 mg, 20 mg and 40 mg OD was 
compared against placebo.[38] There was no significant difference between Tadalafil 20 mg OD 
vs. 40 mg OD with respect to the hemodynamic measures and changes in 6 minute walking 
distance. In the PHIRST-2 extension trial, patients receiving either 20 mg or 40 mg of Tadalafil, 
had both a sustained beneficial effect for up to 52 additional weeks of treatment.[35] The most 
common adverse effect of Tadalafil in this trial was headache, occurring in 14% of patients with 
the 20 mg dose and 28% of patients with the 40 mg dose. Overall, 20 mg Tadalafil seems to 
have benefical cardiovascular effects in PAH patients, but probably less side effects than 40 mg 
Tadalafil. Therefore, in our study Tadalafil 20 mg OD will be compared to placebo. 
 
Explanation for choice of the RVESV as primary outcome measure 
LV dimensions (end-systolic and end-diastolic volumes) and EF have been shown to be one of 
the most powerful predictors of survival in chronic LV heart failure.[39] Dimensions and EF of the 
systemic ventricle are also important prognostic factors in adults with a systemic RV.[7, 40, 41] 
We elected to use changes in RV ESV as primary endpoint for our trial for the following reasons:  
a) In patients with LV systolic dysfunction, short-term therapeutic effects of study drugs or a 
device on LV dimensions were associated with longer-term effects on mortality.[42, 43] We 
assume that the same prognostic assumptions between systemic ventricular volumes and hard 
clinical endpoints can be made for a failing RV: in a recent MRI based study with PAH patients 
and RV failure, RV ESV (but not end-diastolic volumes) at baseline were predictive of late RV 
failure leading to death or lung transplantation after a follow-up of 8 years.[44]  
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b) MRI-based measurements of volumes have the highest reproducibility among all RV 
measures.[45]  
c) Measurement of RV ESV is likely more sensitive to detect changes in RV function in TGA 
patients than RV EF because the RV of patients with PAH adapts to its chronically increased 
afterload first by myocardial remodelling with hypertrophy and increased contractility.[46] If these 
compensatory mechanisms fail, the RV begins to dilate, followed by a decrease in RV EF. 
Accordingly, an increase in RV volumes precedes the decrease in RV EF. The systemic RV in 
patients with TGA may behave similarly. With progressive RV failure and RV dilatation, there is 
also an increase in secondary tricuspid regurgitation.[5] The increased amount of tricuspid 
regurgitation may falsely improve RV EF, whereas RV ESV will nevertheless be increased as 
sign of progressive RV failure.  
d) Performing a placebo-controlled trial that assesses differences in mortality is not feasible in 
TGA patients, as it would need to involve too large patient numbers. 
 
7. Funding  
The SERVE trial is funded by the Swiss National Foundations (Schweizerischer Nationalfonds 
zur Förderung der wissenschaftlichen Forschung, 31IC30_166855) 
 
8. Conclusions 
The objective of this study is to assess the effect of PDE-5 inhibition with Tadalafil on RV size 
and function, exercise capacity and neurohumoral activation in adults with a systemic RV over a 
3-year follow-up period.  
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Table 1 
Inclusion and exclusion criteria of the SERVE trial 
Inclusion 
• Adults (≥18 years) with a systemic RV due to D-TGA repaired with an atrial switch 
procedure or due to ccTGA  
• Signed informed consent 
Exclusion 
• Incapability of giving informed consent  
• Myocardial infarction, stroke, or open heart surgery within the 3 months prior to 
baseline visit 
• Expected heart transplant within the next 6 months starting from baseline  
• Pregnant or nursing women (a pregnancy test is mandatory prior to randomization; 
women of childbearing potential must agree to use reliable contraception from 
randomization to end of study treatment)  
• Severe renal insufficiency (Creatinine clearance ≤ 30 ml/min)  
• Severe hepatic insufficiency (Child-Pugh-Class C)  
• Hypotension with blood pressures < 90/50 mmHg at the baseline visit  
• Hypersensibility to Tadalafil  
• Allergy to iodinated (in patients undergoing CMDCT) or gadolinium-based (in patients 
undergoing CMR) contrast agents 
• Co-medication with nitrates 
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• Regular use of “poppers”, i.e. alkyl nitrites, that are inhaled for recreational purposes, 
including as club drugs used at dance clubs 
• Chronic co-medication with potent CYP3A4 inhibitors: Ketoconazol, Ritonavir, 
Rifampicin  
• Co-medication with other PDE-5 inhibitors for erectile dysfunction during the last four 
weeks prior to baseline visit 
• Medical history of non-arteritic anterior ischemic optic neuropathy  
• Hereditary galactose intolerance, lactase deficiency or glucose-galactose-
malabsorption 
• Participation at another clinical trial in which the primary endpoint has not been 
reached 
ccTGA= congenitally corrected transposition of the great arteries; CMDCT = cardiac multirow 
detector computed tomography; CMR = cardiovascular magnetic resonance imaging;  D-TGA 
= D-transposition of the great arteries; PDE = phosphodiesterase 
 
   
Published in final edited form as : Int J Cardiol. 2017 Sep 15;243:354-359. doi: 10.1016/j.ijcard.2017.05.079 
 
Table 2            
Assessment schedule.           
Visit BL* Visit 
1 
PC1** PC2** PC3** Visit 
2 
PC4** Visit 
3 
PC5** Visit 
4 
Safety 
FU 
Time (months 
from BL) 
0 1  3 6 9 12  18 24  32 36 37  
Window (weeks) 0 ± 2  ±2  ±2  ±2   ±4  ±2  ±4  ±2  ±4  ± 1  
Informed 
Consent 
X           
Eligibility criteria X           
Demography X           
Medical history X           
QoL  X     X    X  
Randomization X           
Clinical 
examination 
X X    X  X  X  
IMP delivery X     X  X    
IMP 
accountability 
 X    X  X  X  
ECG X     X  X  X  
Holter X         X  
CMR / CMDCT X     X    X  
CPET X         X  
Blood analysis X X    X  X  X  
Neurohormones X     X    X  
TTE X     X  X  X  
Concomitant 
Medication 
X X X X X X X X X X  
Adherence   X X X  X  X   
AE/SAE  X X X X X X X X X X 
AE = adverse event; BL = baseline; CMR = ; CMDCT = cardiac multirow detector computed 
tomograph; CPET = cardiopulmonary exercise study; FU= follow-up; IMP = ; PC = phone call; 
QoL = quality of life; SAE = serious adverse event   
 
